Duff & Phelps Investment Management Company reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The hedge fund owned 45,630 shares of the company’s stock after selling 2,190 shares during the period. Duff & Phelps Investment Management Company’s holdings in Johnson & Johnson were worth $4,687,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Lowe FS boosted its position in shares of Johnson & Johnson by 15.2% in the third quarter. Lowe FS now owns 379 shares of the company’s stock worth $35,000 after buying an additional 50 shares in the last quarter. Jennison Associates acquired a new position in shares of Johnson & Johnson during the third quarter worth approximately $3,264,000. Ken Stern & Associates boosted its position in shares of Johnson & Johnson by 10.0% in the third quarter. Ken Stern & Associates now owns 9,050 shares of the company’s stock worth $845,000 after buying an additional 826 shares in the last quarter. Baker Avenue Asset Management boosted its position in shares of Johnson & Johnson by 4.0% in the third quarter. Baker Avenue Asset Management now owns 48,470 shares of the company’s stock worth $4,525,000 after buying an additional 1,871 shares in the last quarter. Finally, Palo Capital boosted its position in shares of Johnson & Johnson by 20.0% in the third quarter. Palo Capital now owns 33,321 shares of the company’s stock worth $3,111,000 after buying an additional 5,560 shares in the last quarter.

Johnson & Johnson (NYSE:JNJ) traded down 0.36% during mid-day trading on Monday, reaching $96.40. 9,350,181 shares of the company’s stock were exchanged. The firm has a market cap of $266.73 billion and a price-to-earnings ratio of 18.50. The stock has a 50-day moving average of $100.75 and a 200-day moving average of $98.59. Johnson & Johnson has a 12 month low of $81.79 and a 12 month high of $105.49.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 8th. Shareholders of record on Tuesday, February 23rd will be given a dividend of $0.75 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.61. The ex-dividend date of this dividend is Friday, February 19th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 3.11%.

A number of research analysts have commented on the stock. Vetr cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating and set a $103.34 price target for the company. in a research note on Tuesday, September 29th. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Thursday, January 7th. Independent Research GmbH set a $105.00 price target on shares of Johnson & Johnson and gave the stock a “neutral” rating in a research note on Thursday. RBC Capital restated an “outperform” rating and set a $114.00 price target on shares of Johnson & Johnson in a research note on Thursday, October 8th. Finally, S&P Equity Research restated a “buy” rating and set a $120.00 price target on shares of Johnson & Johnson in a research note on Thursday, October 15th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $106.92.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

12 Month Chart for NYSE:JNJ

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.